The potential of neutrophil elastase inhibitors as anti-inflammatory therapies

Current Opinion in Hematology

Volumn 21, Issue 1, 2014, Pages 23-28

  Henriksen, Peter A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

elafin; human neutrophil elastase; secretory leucocyte protease inhibitor; sivelestat

Indexed keywords

ALPHA 1 ANTITRYPSIN; AZD 9668; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ELAFIN; HIGH MOBILITY GROUP B1 PROTEIN; ISOTHIOCYANIC ACID; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT ELAFIN; RECOMBINANT PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SIVELESTAT; SULFORAPHANE; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANTIINFLAMMATORY ACTIVITY; BRONCHIECTASIS; CHROMATIN STRUCTURE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; CORONARY ARTERY BYPASS SURGERY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DERMATITIS; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EXTRACELLULAR SPACE; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNOFLUORESCENCE; INTRACELLULAR SIGNALING; LUNG DEVELOPMENT; MACROPHAGE; META ANALYSIS (TOPIC); NEAR INFRARED SPECTROSCOPY; NEUTROPHIL; NONHUMAN; NOSE MUCUS; PERIODONTAL DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SUSTAINED DRUG RELEASE; TRICHOMONIASIS;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; LEUKOCYTE ELASTASE; PROTEINASE INHIBITORY PROTEINS, SECRETORY; REPERFUSION INJURY;

EID: 84890569327     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000001     Document Type: Review

References (27)

1. Pham CT. Neutrophil serine proteases: Specific regulators of inflammation. Nat Rev Immunol 2006; 6:541-550.
2. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: One glove, many fingers. Clin Sci (Lond) 2006; 110:21-35.
3. Saffarzadeh M, Juenemann C, Queisser MA. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: A predominant role of histones. PLoS One 2012; 7:e32366.
4. Skrzeczynska-Moncznik J, Wlodarczyk A, Zabieglo K, et al. Secretory leukocyte proteinase inhibitor-competent DNA deposits are potent stimulators of plasmacytoid dendritic cells: Implication for psoriasis. J Immunol 2012; 189:1611-1617. This study demonstrated that the interaction of SLPI with HNE and DNA within NETs leads to a stimulatory action on plasmacytoid dendritic cells to produce type I interferon. This stimulatory activity requires active HNE and illustrates the complexity of interactions between HNE and its endogenous inhibitors within the neutrophil subcellular space.
5. Kerrin A, Weldon S, Chung AH, et al. Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury. Thorax 2013; 68:315-321. This article identifies 20S proteosome activity within the extracellular space as being responsible for the degradation of elafin in patients with acute lung injury. This contributes to reduction in bronchoalveolar elafin (but not SLPI) content over 7 days and may contribute to sustained inflammation in these patients.
6. Motta JP, Bermudez-Humaran LG, Deraison C, et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012; 4:158ra144. This proof-of-principle study demonstrated that safe bacteria expressing and secreting human elafin protect mice and reduce neutrophil elastase-mediated inflammation in models of inflammatory bowel disease. The bacteria also protected cultured human intestinal epithelial cells from inflammatory injury indicating a well tolerated and effective method for therapeutic elafin delivery in this disease.
7. Laugisch O, Schacht M, Guentsch A, et al. Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid. Mol Oral Microbiol 2012; 27:45-56.
8. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:1117-1124.
9. Brea D, Meurens F, Dubois AV, et al. The pig as a model for investigating the role of neutrophil serine proteases in human inflammatory lung diseases. Biochem J 2012; 447:363-370.
10. Kossodo S, Zhang J, Groves K, et al. Noninvasive in vivo quantification of neutrophil elastase activity in acute experimental mouse lung injury. Int J Mol Imaging 2011; 2011:581406.
11. Carter RI, Mumford RA, Treonze KM, et al. The fibrinogen cleavage product Aa-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax 2011; 66:686-691.
12. Carter RI, Ungurs MJ, Mumford RA, Stockley RA. Aa-Val360: A marker of neutrophil elastase and COPD disease activity. Eur Respir J 2013; 41:31-38. Validation of Aa-Val360 as a marker of disease severity and acute exacerbations in patients with chronic obstructive pulmonary disease.
13. Barros SC, Martins JA, Marcos JC, Cavaco-Paulo A. Influence of secretory leukocyte protease inhibitor-based peptides on elastase activity and their incorporation in hyaluronic acid hydrogels for chronic wound therapy. Biopolymers 2012; 98:576-590. Development of a topical delivery system harnessing the putative wound healing properties of SLPI-derived peptides.
14. Reibetanz U, Schonberg M, Rathmann S, et al. Inhibition of human neutrophil elastase by alpha1-antitrypsin functionalized colloidal microcarriers. ACS Nano 2012; 6:6325-6336.
15. Moreau T, Baranger K, Dade S, et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90:284-295.
16. Alam SR, Newby DE, Henriksen PA. Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: From epithelium to endothelium. Biochem Pharmacol 2012; 83:695-704. A review of the substantial preclinical work indicating the therapeutic potential of elafin in cardiovascular disease.
17. Hilgendorff A, Parai K, Ertsey R, et al. Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth. Am J Physiol Lung Cell Mol Physiol 2012; 303:L215-L227. This group have characterized the elastase-mediated inflammatory effects of high flow oxygen and ventilation in neonates. Mice expressing human elafin within the pulmonary vasculature were protected from excessive elastase activity including elastin breakdown and structural lung abnormality, indicating the utility of elafin in this disease that has no effective treatment.
18. Meyer M, Kesic MJ, Clarke J, et al. Sulforaphane induces SLPI secretion in the nasal mucosa. Respir Med 2013; 107:472-475.
19. Motta JP, Magne L, Descamps D, et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011; 140:1272-1282.
20. Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): A systematic review and meta-analysis. Intern Med 2010; 49:2423-2432.
21. Miyoshi S, Hamada H, Ito R. Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis. Drug Des Devel Ther 2013; 7:305-316.
22. Makino H, Kunisaki C, Kosaka T, et al. Perioperative use of a neutrophil elastase inhibitor in video-assisted thoracoscopic oesophagectomy for cancer. Br J Surg 2011; 98:975-982.
23. Tsujii S, Okabayashi T, Shiga M, et al. The effect of the neutrophil elastase inhibitor sivelestat on early injury after liver resection. World J Surg 2012; 36:1122-1127.
24. Vogelmeier C, Aquino TO, O'Brien CD, et al. A randomised, placebocontrolled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD 2012; 9:111-120. The largest multicentre randomized controlled trial examining three doses of AZD9668 and placebo in 838 patients with COAD over a 3-month period.
25. Kuna P, Jenkins M, O'Brien CD, et al. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med 2012; 106:531-539. A further randomized controlled study with AZD9668 in COAD patients recruiting 615 patients to 60 mg b.i.d. dose compared with placebo for a 3-month treatment period.
26. Elborn JS, Perrett J, Forsman-Semb K, et al. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J 2012; 40:969-976. A randomized controlled study with 56 cystic fibrosis patients examining a 4-week treatment with AZD9668. Outcome measures included lung function, sputum volume, a range of inflammatory markers within the sputum and urinary desmosines.
27. Stockley R, De SA, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013; 107:524-533.